Adocia (Euronext Paris:ADOC), a clinical-stage biopharmaceutical company focused on diabetes and obesity treatments, on Wednesday announced the filing of a patent for its new long-acting peptide platform, AdoXLong.

The technology uses a biocompatible polymer to extend peptide activity to at least one month without altering their mechanism of action, allowing subcutaneous administration with standard injection devices.

Initial studies with semaglutide show promising in vitro and in vivo results compatible with a once-monthly dosing schedule. The platform is designed for a broad range of peptides, including GLP-1, GIP, amylin, and dual or triple agonists, and can potentially combine multiple modified peptides.

The patent, if granted, would provide worldwide protection until 2046 and reinforce intellectual property for both innovative and biosimilar peptides, including semaglutide, which becomes off-patent in some regions in 2026.

Separately, Adocia continues to develop its BioChaperone platform, with two ongoing feasibility studies in collaboration with large undisclosed pharmaceutical companies, aimed at stabilising and combining hormones for diabetes and obesity therapies.